Metastatic triple-negative breast inflammatory carcinoma

Clinical trials for Metastatic triple-negative breast inflammatory carcinoma explained in plain language.

Never miss a new study

Get alerted when new Metastatic triple-negative breast inflammatory carcinoma trials appear

Sign up with your email to follow new studies for Metastatic triple-negative breast inflammatory carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

Promising combo for inflammatory breast cancer stalls after single patient

Disease control Stopped early

This early-phase trial tested a combination of two drugs—icosapent ethyl (an omega-3 fatty acid) and dasatinib (a targeted cancer drug)—in people with a rare, aggressive form of breast cancer that had spread. The goal was to find a safe dose and see if the combo could shrink tumo…

Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST INFLAMMATORY CARCINOMA

Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jun 27, 2026 07:53 UTC

Metastatic triple-negative breast inflammatory carcinoma

Get alerted when new Metastatic triple-negative breast inflammatory carcinoma trials appear

Promising combo for inflammatory breast cancer stalls after single patient